NASDAQ:VTVT vTv Therapeutics Q2 2025 Earnings Report $32.76 +1.17 (+3.70%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$32.76 +0.01 (+0.02%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast vTv Therapeutics EPS ResultsActual EPS-$0.92Consensus EPS -$0.85Beat/MissMissed by -$0.07One Year Ago EPSN/AvTv Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AvTv Therapeutics Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time8:00AM ETUpcoming EarningsvTv Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) vTv Therapeutics Earnings HeadlinesvTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 4, 2026 | americanbankingnews.comvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 2, 2026 | globenewswire.comSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $1.75 trillion valuation and 266 times earnings, you're buying in at the most expensive IPO in history - right when institutions who got in at $800 billion need someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure Colossus can't run without - and it's still trading at a fraction of its value.June 14 at 1:00 AM | Behind the Markets (Ad)vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen NextMay 17, 2026 | finance.yahoo.comvTv Therapeutics Expands At-The-Market Share Program CapacityMay 13, 2026 | tipranks.comvTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comSee More vTv Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like vTv Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on vTv Therapeutics and other key companies, straight to your email. Email Address About vTv TherapeuticsvTv Therapeutics (NASDAQ:VTVT), Inc. is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties. The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease. In parallel, vTv is advancing TTP399, a liver-selective glucokinase activator designed as an adjunctive therapy for type 1 diabetes. These programs exemplify vTv’s strategy of targeting high-need indications with differentiated oral therapies. Since its inception, vTv Therapeutics has pursued strategic collaborations and licensing agreements to support its clinical development efforts and potential commercialization. While primarily operating in the United States, the company actively seeks global partnerships to extend the reach of its pipeline. Led by a management team with extensive experience in pharmaceutical research, clinical development and regulatory affairs, vTv remains committed to progressing its candidates through pivotal trials toward regulatory approval.View vTv Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?TJX: Retail’s Apex Predator Feasts on InflationWhy Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors EarsThis Energy Stock Has Quietly Soared 130% in a YearCracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressChewy’s Growth Engine Is Stronger Than the Market Thinks Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
